A recent meta-analysis of icodec insulin in patients with T2DM, including only the 3 phase 2 studies, showed a significant reduction in HbA1c, albeit of smaller magnitude (-0.20%; 95% CI: -0.33, -0.07%; P=0.002), with an increase in TIR (+6.6%), without a significant increase in hypoglycemia compared to glargine U100 insulin (59). The gene discussed is INS; the disease is type 2 diabetes mellitus.